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Abstract 
Clinical and research networks for rare conditions are increasingly common nowadays. Given 
the rarity of many such conditions, there is a need to cover more conditions yet there is also a 
need to sustain and improve the quality and effectiveness of existing networks. This review will 
discuss the qualities that are required by a virtual network using some international clinical and 
research networks that are currently active in the field of rare endocrine conditions affecting sex 
and adrenal development as exemplars.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
Introduction  
There are approximately 5000 to 8000 rare diseases or conditions that affect 6-8% of the 
population (1). Patients with these conditions are often isolated and experience significant 
obstacles in accessing high quality healthcare and information. Research activity for these 
conditions is often poorly coordinated and lacks quality and effectiveness. The group of 
conditions, collectively labelled as Disorders of Sex Development (DSD), is a typical example 
where there is a substantial lack of knowledge about aetiology and long term outcome and 
initiatives in research are limited by the low prevalence of individual conditions and the scarcity 
of resources and expertise at a local level. Whilst centres of expertise can bring together 
multidisciplinary competencies around the needs of patients, the creation of virtual networks is 
becoming a necessity to coordinate the work of these nodes, speed up the pace of discovery by 
pooling scarce resources and ensure patient empowerment by creating a common strong voice 
on behalf of these patients.  
 
The ideal qualities of a virtual network for rare conditions 
An ideal virtual network for rare conditions places patient welfare at the heart of the project.  It 
should be governed by a board composed of representatives of all stakeholders including 
advocacy groups, policymakers, researchers and clinicians, industry and Ethics and patients 
that play a central role in determination of priorities and evaluation of activities (2). This 
governing body ensures sustainability of the project, deals with administrative, ethical and legal 
issues and ensures coordination of all parties involved in the network. It also ensures 
communication and dissemination of activities to external members using various means 
including websites, newsletters, institutional bulletins, scientific meetings and peer-reviewed 
journals and creates and maintains secure infrastructures for communication between internal 
members that are organised on a regular basis so that the members can express their needs, 
share experiences and coordinate work. This communication is key to collaboration within a 
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high quality network so that fragmented initiatives in patient care and research can be 
consolidated into common projects that optimise the rational use of scarce financial and human 
resources and prevent duplication of effort. Good communication will also lead to a common 
vision which will be derived from similar challenges and creating consensus around disparate 
priorities in a democratic way. Within a network that focuses on clinical care, research priorities 
should be defined by all stakeholders and centered at patients’ needs and preferences. A 
strategic plan should also be defined as well as standard operating procedures that govern 
research activities including sharing of data and bio-specimens. Registries and biobanks that 
are interoperable across geographical boundaries are the backbone of these research activities 
to allow pooling of data to reach sufficient statistically significant numbers for clinical research 
and public health purposes (3). There is also a need for linking existing biological samples to 
data in patient registries. To accelerate the pace of drug discovery, collaboration with industry is 
also needed and this can be best realised through the registries as well as the potential to 
deliver trials through a network of high quality clinical centres. By allowing efficient and secure 
communication between physicians to share experiences and discuss challenging cases, and 
by reducing the need for patients and professionals, networks for rare conditions can also have 
a direct impact on day to day health care. The traditional healthcare system which is often 
limited by financial and geographical constraints could be replaced by a patient centered system 
with equal access to multidisciplinary care and treatment across the lifespan and across 
geographic boundaries. Patients and their representatives should play a central role in all these 
network processes pertaining both clinical care and research activities as informed, engaged 
and interactive partners. The network should also implement capacity-building programmes to 
empower patient representatives with the knowledge and skills they need to ensure these roles 
(4) and increase general awareness by implementing educational programmes for both patients 
and the medical community. Due to the limited number of patients and experts in a local level, 
the network should have an international coverage to bring together national and regional 
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initiatives from around the world and advocate for rare disease as an international public health 
priority. To balance wide coverage of conditions and detailed focus on conditions, disparate 
networks of rare conditions should be integrated under a wider network that covers all these 
conditions to empower their position and coordinate their efforts. Having a network with 
common and standard operating protocols that are approved by regulatory agencies such as 
those that deal with ethics or information governance greatly helps existing as well as new 
members of the network. These ideal qualities of virtual networks for rare conditions are 
summarised in Table 1.  
 
International Networks in DSD   
Several countries have DSD networks that organise patient care and research at a regional or 
national level (9, 10, 11). The importance of pooling the efforts of these national and regional 
networks into international projects has been emphasized by many European and international 
initiatives in rare diseases such as EURORDIS (European Organization for Rare Diseases), 
EUCERD (European Union Committee of Experts on Rare Diseases)  and IRDiRC (International 
Rare Diseases Research Consortium). Some networks that have been created to work across 
international boundaries with an objective to improve clinical care, knowledge and research are 
discussed below.  
 
I-DSD (www.i-dsd.org) 
I-DSD is a registry based network and a model of collaborative international research that, at 
last review in March 2017, linked 61 centres from 31 countries from 5 continents, and allowed 
experts to enter standardised information aimed at improving clinical practice and research in 
DSD. The registry adheres to international standards that were set for high quality registries 
(12). It has a strong governance model which represents several stakeholders including 
patients. This governing body has a good oversight, ensures long term sustainability and 
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establishes standard operating procedures regulating all ethical and legal aspects. These 
registry protocols have been approved by ethics committees and sharing of data takes into 
account the rules for security, confidentiality and informed consent. Data quality assurance 
procedures have also been implemented to ensure high quality data that enabled several types 
of studies ranging from basic research aiming at characterizing the DSD population (13) to 
those exploring trends in practice (14,15) and contributing to better outcome of patients. The 
registry communicates the results of these studies and information about ongoing and future 
studies to a range of stakeholders through regular presentations at scientific meetings, via a 
website and through newsletters. A web-based module has also been created enabling patients 
to stay informed about registry activities to view their data and express their preferences in 
healthcare and research. By enabling such effective interactions, the I-DSD Registry is 
becoming a platform for international networking that allows the users to play leading roles in 
initiativessuch as EuroDSD, DSDlife, DSDnet, the recent global DSD update (16) the response 
to the EU Commissioner (17), a survey of DSD centres (10), a survey of clinical psychology 
support at DSD centres, and a biennial international meeting for DSD. Future directions are 
further development of the newly created patient web based module to provide more 
personalised information for patients, allow collection of patient reported outcomes and 
experiences in their own language and create a space where they can communicate with their 
clinicians. Each patient will have a unique global identifier that can allow linkage of their data 
through all databases and biobanks and the dataset will be revised to improve its interoperability 
with other registries. The registry is evolving towards covering additional modules involved in 
DSD care such as surgery, psychology, fertility, and is broadening its scope to cover more 
conditions.  
 
I-CAH (www.i-cah.org) 
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An international network of researchers and clinicians looking after people with congenital 
adrenal hyperplasia (CAH) was created to speed up the pace of discovery of new management 
strategies and therapies and optimise the outcome of patients with CAH. This network is 
managed and administered by the I-DSD governing body and was supported by the TAIN 
project (Treatment of Adrenal Insufficiency in Neonates) which was an EU funded consortium 
dedicated to developing a new formulation of hydrocortisone. With the newly-created I-CAH 
Registry as its centrepiece, the network is supporting a number of longitudinal studies such as a 
study examining adverse events and a study of fludrocortisone and salt therapy. The 
longitudinal module also enables the registry to be used as a clinical tool in a clinic setting and 
enables the network to play a vital role in benchmarking clinical outcomes in order to improve 
the quality of care. This module is also the starting point for developing the infrastructure, 
compliance and quality framework to enable elements of the registry to be used as a post-
marketing surveillance tool. I-CAH also supports patients and parents by providing educational 
material, support and links in different langages and organising educational days for patients 
and families. A new module will be developed to collect data on outcomes directly from patients 
including information on quality of life, adverse events and endocrine management and will be 
used as a personalised resource for patients and parents. These personal information could 
complement medical data provided by clinicians and help them to evaluate their practice from a 
patient view in order to optimize the holistic care for patients in DSD.  
 
DSDnet (www.dsdnet.eu) 
DSDnet is an international network of 19 European and 9 affiliated international partners that 
links scientists with professionals, patient support groups and policy makers in order to improve 
clinical care and promote research in DSD. This initiative is funded by a COST action (European 
Cooperation in Science and Technology) and five working groups were created composed by 
international experts with specfic duties working in close collaboration. DSDnet aims to promote 
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the development of partnerships that will allow improved elucidation of the cause of all forms of 
DSD. It also aimed at developing consensus on the assessment of clinical phenotype and and 
that can be incorporated into registries such as I-DSD and I-CAH. Other activties include the 
harmonisation of diagnostic investigations as well as a collaboration with patients and 
professionals. Patients and advocacy groups are actively involved and through holding a 
workshop the network is integrating their views into clinical and research guidelines. DSDnet 
has also played a central role in the European Reference Network (ERN) project by designation 
of centres of expertise in DSD. The network is also supporting training and research of early 
stage professionals by organising training schools and short term scientific missions that 
strengthens collaboration between centres. DSDnet is promoting research proposals and results 
are disseminated through scientific papers and meetings, via the website  and the press in order 
to inform all stakeholders including political decision bodies. 
 
ENSAT Registry (www.ensat.org) 
ENSAT-CANCER is an EU-FP7 funded initiative dedicated to develop prediction and 
management of adrenal tumors. This is a virtual research network that connects specialized 
clinicians with research communities to conduct collaborative research in malignant adrenal 
tumours. This digitally interconnected infrastructure collects data in a secure platform and 
places a great emphasis in biobanking and other enabling services including sample barcoding, 
bio-sample exchange mechanisms, an integrated linkage scheme to other trials and studies, 
summary statistics, report generation and image hosting (18). Projects are focused on studying 
genetics and treatment of adrenal tumors, discovering new molecular mechanisms of their 
growth,  and providing insight into associated areas, such as the role of peptides and steroids in 
hypertension. The project has demonstrated its ability to conduct international collaborative 
research by collecting data and biomaterial of a large number of cases despite the rarity of 
these tumours, importing new data-sets from other smaller country specific repositories, and 
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supporting large data export projects in order to perform several types of studies including 
clinical trials in collaboration with pharmaceutical companies.  
 
Interaction of registry-based detailed disease networks with European Reference 
Networks 
The Chicago consensus Conference (19) and the UK guidance on the initial evaluation of an 
infant or an adolescent with DSD (20) led to significant changes in the management of patients 
at an international as well as a local level. However, an international survey of 124 paediatric 
endocrinologists in 2014 reported that only 40% of DSD centres had a sufficiently adequate 
multidisciplinary team for quality care of patients and there were substantial variations in 
practices and access to specialist tests between these centres (10). Through the preparatory 
work for Endo-ERN, the European Reference Network for rare endocrine conditions, DSDnet 
has embarked on the development of criteria for centres of expertise for DSD. DSD and 
Congenital Adrenal Hyperplasia are two of the eight themes that will be covered by Endo-ERN 
(https://endo-ern.eu/), which was approved in December 2016, and is the largest ERN with 71 
health care providers from 19 member states. The creation of this ERN for DSD will optimise 
possibilities for better patient management, by improving diagnostic trajectories between 
national healthcare providers and centres of expertise, ensuring access to multidisciplinary care 
across the lifespan, and equity of access to treatments, in order to improve the quality of life and 
socioeconomic potential of DSD patients. Communication between centres will allow better 
management of variations in practices, rational utilisation of clinical genetics and biochemistry 
and the development of clinical guidelines, new evidence based care models, e-health solutions 
and e-tools for tele-expertise and tele-consultation as well as e-learning and training 
opportunities for professional development. In terms of research, the creation of a common core 
endocrine registry will allow existing detailed disease registries to interact with each other and 
with other registries within Endo-ERN and beyond within a framework that will adhere to the 
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FAIR principles where data are findable, accessible, interoperable and re-usable (21). It is 
anticipated that participation in this registry will become a pre-requisite of centres of expertise 
that are members of Endo-ERN and will allow these centres to participate in benchmarking 
exercises that lead to quality improvement. In terms of patient involvement, a workshop was 
organised in Bologna in October 2016 by DSDnet in order to identify the needs of DSD patients 
in research,  healthcare and education. Patients and families were also introduced to the project 
of ERN for DSD and to the concept of European Patient Advocacy Groups (ePAGs) that was 
developed by EURORDIS. These advocacy groups ensure that the DSD patient voice is heard 
throughout the Endo-ERN development process and allows the integration of the needs and 
preferences of patients with DSD into clinical care, education and research.  
 
Conclusion   
Coordinated networks for rare conditions are becoming a necessity to prevent duplication of 
work and to maximise the benefit of pooling resources and expertise. The use of new 
technologies has significantly promoted communication and collaboration between different 
stakeholders including patients and further attention needs to be paid to ensure long term 
sustainability.  
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